FASEB J. Mp Biomedicals
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
fj.07-9909comv1
22/5/1572    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hudson, B. I.
Right arrow Articles by Schmidt, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hudson, B. I.
Right arrow Articles by Schmidt, A. M.
Published online before print December 18, 2007 as doi: 10.1096/fj.07-9909com.

Identification, classification, and expression of RAGE gene splice variants

Barry I. Hudson, Angela M. Carter, Evis Harja, Anastasia Z. Kalea, Maria Arriero, Hojin Yang, Peter J Grant, and Ann Marie Schmidt

E-mail contact: bh2021@columbia.edu

The receptor for advanced glycation end-products (RAGE) is a single-transmembrane, multiligand receptor of the immunoglobulin superfamily. RAGE up-regulation is implicated in numerous pathological states including vascular disease, diabetes, cancer, and neurodegeneration. The understanding of the regulation of RAGE is important in both disease pathogenesis and normal homeostasis. Here, we demonstrate the characterization and identification of human RAGE splice variants by analysis of RAGE cDNA from tissue and cells. We identified a vast range of splice forms that lead to changes in the protein coding region of RAGE, which we have classified according to the Human Gene Nomenclature Committee (HGNC). These resulted in protein changes in the ligand-binding domain of RAGE or the removal of the transmembrane domain and cytosolic tail. Analysis of splice variants for premature termination codons reveals~50% of identified variants are targeted to the nonsense-mediated mRNA decay pathway. Expression analysis revealed the RAGE_v1 variant to be the primary secreted soluble isoform of RAGE. Taken together, identification of functional splice variants of RAGE underscores the biological diversity of the RAGE gene and will aid in the understanding of the gene in the normal and pathological state. —Hudson, B. I., Carter, A. M., Harja, E., Kalea, A. Z., Arriero, M., Yang, H., Grant, P. J., Schmidt, A. M. Identification, classification, and expression of RAGE gene splice variants.




This article has been cited by other articles:


Home page
 Circ. Res.Home page
S. F. Yan, R. Ramasamy, and A. M. Schmidt
The RAGE Axis: A Fundamental Mechanism Signaling Danger to the Vulnerable Vasculature
Circ. Res., March 19, 2010; 106(5): 842 - 853.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. Rojas, H. Figueroa, and E. Morales
Fueling inflammation at tumor microenvironment: the role of multiligand/rage axis
Carcinogenesis, March 1, 2010; 31(3): 334 - 341.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. H. J. Gaens, I. Ferreira, C. J. H. van der Kallen, M. M. J. van Greevenbroek, E. E. Blaak, E. J. M. Feskens, J. M. Dekker, G. Nijpels, R. J. Heine, L. M. 't Hart, et al.
Association of Polymorphism in the Receptor for Advanced Glycation End Products (RAGE) Gene with Circulating RAGE Levels
J. Clin. Endocrinol. Metab., December 1, 2009; 94(12): 5174 - 5180.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
H. Maillard-Lefebvre, E. Boulanger, M. Daroux, C. Gaxatte, B. I. Hudson, and M. Lambert
Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases
Rheumatology, October 1, 2009; 48(10): 1190 - 1196.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
R. Ramasamy, S. F. Yan, and A. M. Schmidt
RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts
J. Leukoc. Biol., September 1, 2009; 86(3): 505 - 512.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C. S. Buhimschi, M. A. Baumbusch, A. T. Dulay, E. A. Oliver, S. Lee, G. Zhao, V. Bhandari, R. A. Ehrenkranz, C. P. Weiner, J. A. Madri, et al.
Characterization of RAGE, HMGB1, and S100{beta} in Inflammation-Induced Preterm Birth and Fetal Tissue Injury
Am. J. Pathol., September 1, 2009; 175(3): 958 - 975.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Zhang, M. Bukulin, E. Kojro, A. Roth, V. V. Metz, F. Fahrenholz, P. P. Nawroth, A. Bierhaus, and R. Postina
Receptor for Advanced Glycation End Products Is Subjected to Protein Ectodomain Shedding by Metalloproteinases
J. Biol. Chem., December 19, 2008; 283(51): 35507 - 35516.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes and Vascular Disease ResearchHome page
N. Katakami, M. Matsuhisa, H. Kaneto, T.-A. Matsuoka, K. Sakamoto, T. Yasuda, and Y. Yamasaki
Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients
Diabetes and Vascular Disease Research, September 1, 2008; 5(3): 190 - 197.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by The Federation of American Societies for Experimental Biology.